Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 170

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Window-of-opportunity clinical trial of pembrolizumab in patients with recurrent glioblastoma reveals predominance of immune-suppressive macrophages

Open access
de Groot, John, Penas-Prado, Marta, Alfaro-Munoz, Kristin, Hunter, Kathy, Pei, Be Lian, O’Brien, Barbara, Weathers, Shiao-Pei, Loghin, Monica, Kamiya Matsouka, Carlos, Yung, W K Alfred, Mandel, Jacob, Wu, Jimin, Yuan, Ying, Zhou, Shouhao, Fuller, Gregory N, Huse, Jason, Rao, Ganesh, Weinberg, Jeffrey S, Prabhu, Sujit S, McCutcheon, Ian E, Lang, Frederick F, Ferguson, Sherise D, Sawaya, Raymond, Colen, Rivka, Yadav, Shalini S, Blando, Jorge, Vence, Luis, Allison, James, Sharma, Padmanee, Heimberger, Amy B · 2020 · Neuro-Oncology

Abstract

Background: We sought to ascertain the immune effector function of pembrolizumab within the glioblastoma (GBM) microenvironment during the therapeutic window. Methods: In an open-label, single-center, single-arm phase II “window-of-opportunity” trial in 15 patients with recurrent (operable) GBM receiving up to 2 pembrolizumab doses before surgery and every 3 weeks afterward until disease progression or unacceptable toxicities occurred, immune responses were evaluated within the tumor. Results: No treatment-related deaths occurred. Overall median follow-up time was 50 months. Of 14 patients monitored, 10 had progressive disease, 3 had a partial response, and 1 had stable disease. Median progression-free survival (PFS) was 4.5 months (95% CI: 2.27, 6.83), and the 6-month PFS rate was 40%. Median overall survival (OS) was 20 months, with an estimated 1-year OS rate of 63%. GBM patients’ recurrent tumors contained few T cells that demonstrated a paucity of immune activation markers, but the tumor microenvironment was markedly enriched for CD68+ macrophages. Conclusions: Immune analyses indicated that pembrolizumab anti–programmed cell death 1 (PD-1) monotherapy alone can’t induce effector immunologic response in most GBM patients, probably owing to a scarcity of T cells within the tumor microenvironment and a CD68+ macrophage preponderance.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/neuonc/noz185

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Cited by

See all 170

Metadata

Authors
de Groot, J., Penas-Prado, M., Alfaro-Munoz, K., Hunter, K., Pei, B. L., O’Brien, B., Weathers, S.-P., Loghin, M., Kamiya Matsouka, C., Yung, W. K. A., Mandel, J., Wu, J., Yuan, Y., Zhou, S., Fuller, G. N., Huse, J., Rao, G., Weinberg, J. S., Prabhu, S. S., McCutcheon, I. E., Lang, F. F., Ferguson, S. D., Sawaya, R., Colen, R., Yadav, S. S., Blando, J., Vence, L., Allison, J., Sharma, P., & Heimberger, A. B.
Venue
Neuro-Oncology
Published
2019-11-22
Volume
22
Issue
4
Pages
539-549
ISSN
  • 1522-8517 (ISSN-L)
  • 1523-5866
OpenAlex
W2996809166
Cited by
170
References
8
FWCI
7.41
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Window-of-opportunity clinical trial of pembrolizumab in patients with recurrent glioblastoma reveals predominance of immune-suppressive macrophages. https://app.cochat.ai/papers/10.1093/neuonc/noz185
The paper
de Groot, J., Penas-Prado, M., Alfaro-Munoz, K., Hunter, K., Pei, B. L., O’Brien, B., Weathers, S.-P., Loghin, M., Kamiya Matsouka, C., Yung, W. K. A., Mandel, J., Wu, J., Yuan, Y., Zhou, S., Fuller, G. N., Huse, J., Rao, G., Weinberg, J. S., Prabhu, S. S., . . . Heimberger, A. B. (2020). Window-of-opportunity clinical trial of pembrolizumab in patients with recurrent glioblastoma reveals predominance of immune-suppressive macrophages. Neuro-Oncology. https://doi.org/10.1093/neuonc/noz185

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.